Spring Research Update Meeting 2025
Our 2025 Spring Research Update Meeting will take place at BMA House, home of the British Medical Association, in Tavistock Square, London on 24 March where we invite guests to an inspiring agenda of some of the most up to date news of our funded...
Learn more
Phase 1a trial findings of iLCT prioritised drug, Anle138b
The findings of the phase 1a clinical trial of Anle138b have been published. Anle138b is a new drug that targets the build-up of alpha synuclein, a protein that clumps together in Parkinson’s.
Our Spring Newsletter
Download your interactive PDF copy here now!
Spring Research Update Meeting 2022 – recorded to watch again
Theme: Why diabetes drugs might be an important potential line of treatment for Parkinson’s. The meeting was recorded and is available to re-watch now
New mRNA activators for Parkinson’s
Research evidence has suggested that in Parkinson’s there is some disruption to a process involved in protein production within cells. This process is known as ‘m6A mRNA methylation’, and activation of this process may protect nerve cells against Parkinson’s. Laboratory research has shown that supporting…
The lonafarnib pre-clinical study
This research led by Professor Joe Mazzulli, will, it is hoped, give us a better understanding of how lonafarnib can reduce the build-up of the toxic protein alpha-synuclein which is a characteristic of Parkinson’s.